» Articles » PMID: 20857871

The Injection of Hypocretin-1 into the Nucleus Pontis Oralis Induces Either Active Sleep or Wakefulness Depending on the Behavioral State when It is Administered

Overview
Journal Sleep
Specialty Psychiatry
Date 2010 Sep 23
PMID 20857871
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: We previously reported that the microinjection of hypocretin (orexin) into the nucleus pontis oralis (NPO) induces a behavioral state that is comparable to naturally occurring active (rapid eye movement) sleep. However, other laboratories have found that wakefulness occurs following injections of hypocretin into the NPO. The present study tested the hypothesis that the discrepancy in behavioral state responses to hypocretin injections is due to the fact that hypocretin was not administered during the same states of sleep or wakefulness.

Design: Adult cats were implanted with electrodes to record sleep and waking states. Hypocretin-1 (0.25 microL, 500microM) was microinjected into the NPO while the animals were awake or in quiet (non-rapid eye movement) sleep.

Measurements And Results: When hyprocretin-1 was microinjected into the NPO during quiet sleep, active sleep occurred with a short latency. In addition, there was a significant increase in the time spent in active sleep and in the number of episodes of this state. On the other hand, the injection of hyprocretin-1 during wakefulness resulted not only in a significant increase in wakefulness, but also in a decrease in the percentage and frequency of episodes of active sleep.

Conclusions: The present data demonstrate that the behavioral state of the animal dictates whether active sleep or wakefulness is induced following the injection of hypocretin. Therefore, we suggest that hypocretin-1 enhances ongoing states of wakefulness and their accompanying patterns of physiologic activity and that hypocretin-1 is also capable of promoting active sleep and the changes in various processes that occur during this state.

Citing Articles

Excessive daytime sleepiness in a model of Parkinson's disease improved by low-frequency stimulation of the pedunculopontine nucleus.

Davin A, Chabardes S, Devergnas A, Benstaali C, Gutekunst C, David O NPJ Parkinsons Dis. 2023; 9(1):9.

PMID: 36697421 PMC: 9876933. DOI: 10.1038/s41531-023-00455-7.


Consciousness loss during epileptogenesis: implication for VLPO-PnO circuits.

Feng M, He Z, Liu B, Li Z, Tao G, Wu D Int J Physiol Pathophysiol Pharmacol. 2017; 9(1):1-7.

PMID: 28337311 PMC: 5344992.


The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep.

Arrigoni E, Chen M, Fuller P J Physiol. 2016; 594(19):5391-414.

PMID: 27060683 PMC: 5043043. DOI: 10.1113/JP271324.


The hypocretins (orexins) mediate the "phasic" components of REM sleep: A new hypothesis.

Torterolo P, Chase M Sleep Sci. 2015; 7(1):19-29.

PMID: 26483897 PMC: 4521687. DOI: 10.1016/j.slsci.2014.07.021.


Hypocretinergic and non-hypocretinergic projections from the hypothalamus to the REM sleep executive area of the pons.

Torterolo P, Sampogna S, Chase M Brain Res. 2012; 1491:68-77.

PMID: 23122879 PMC: 3529971. DOI: 10.1016/j.brainres.2012.10.050.

References
1.
Dauvilliers Y, Baumann C, Carlander B, Bischof M, Blatter T, Lecendreux M . CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry. 2003; 74(12):1667-73. PMC: 1757412. DOI: 10.1136/jnnp.74.12.1667. View

2.
Kiyashchenko L, Mileykovskiy B, Maidment N, Lam H, Wu M, John J . Release of hypocretin (orexin) during waking and sleep states. J Neurosci. 2002; 22(13):5282-6. PMC: 6758234. DOI: 20026541. View

3.
Zhang J, Sampogna S, Morales F, Chase M . Distribution of hypocretin (orexin) immunoreactivity in the feline pons and medulla. Brain Res. 2003; 995(2):205-17. DOI: 10.1016/j.brainres.2003.10.004. View

4.
de Lecea L, Kilduff T, Peyron C, Gao X, Foye P, Danielson P . The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998; 95(1):322-7. PMC: 18213. DOI: 10.1073/pnas.95.1.322. View

5.
Nishino S, Ripley B, Overeem S, Lammers G, Mignot E . Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000; 355(9197):39-40. DOI: 10.1016/S0140-6736(99)05582-8. View